EU agency recommends Sanofi, Merck pediatric vaccine

(Reuters) – The European Medicines Agency recommended approval of Hexyon, a new 6-in-1 pediatric vaccine from Sanofi Pasteur MSD, a joint venture between Merck and Sanofi, the ...

Lyrica matches UCB drug in Pfizer’s latest epilepsy trial

By Tracy Staton Pfizer’s attempts to prove Lyrica effective as an epilepsy treatment have delivered mixed results. Just three months ago, the controlled-release formula failed ...

Abbott inks companion Dx deal for J&J’s ‘breakthrough’ cancer drug

By Damian Garde Johnson & Johnson ($JNJ) scored a major victory with the FDA this month when the agency put its breakthrough designation on an investigational cancer drug, and ...

Italian antitrust agency probes alleged Roche-Novartis cartel

Eye docs, clinics want to use Avastin, but Lucentis is the only approved option By Tracy Staton  Italian antitrust watchdogs have entered the Avastin-vs.-Lucentis fray. The Italian ...

Novartis nabs another FDA-approved indication for everolimus

By Tracy Staton Turns out, everolimus is becoming quite the franchise for Novartis ($NVS). Sold under the Afinitor and Votubia names for tumor treatment and as Zortress and Certican ...

Particulates raise concerns about Gilead’s Vistide

Manufacturing challenges don’t deter interest in growth area By Eric Palmer Sterile injectable drugs are a growing business that more companies would like to get into. But the ...

Takeda preps for first Actos trial now opening in L.A.

By Tracy Staton  The first trial of a lawsuit linking the diabetes drug Actos with bladder cancer is about to begin. As Bloomberg reports, jury selection starts today in Los ...

Vioxx and Diclofenac: Why Are Two Heart Risky Pain Drugs Viewed Differently?

By John LaMattina More than a decade ago, Mercklaunched Vioxx (rofecoxib),  one of the first of a new class of pain relievers known as COX-2 inhibitors. These compounds, by virtue ...

Merck to pay $668 million to settle drug-trial disclosure suits

By David Sell Merck & Co. said Thursday that it would pay $668 million to settle two class-action lawsuits by investors who accused the company of not properly disclosing the ...

GSK wins priority status for new HIV drug in U.S

LONDON (Reuters) – U.S. regulators gave priority review status to an experimental GlaxoSmithKlinedrug for HIV/AIDS, which industry analysts view as a possible multibillion-dollar-a-year ...

Shire’s Vyvanse tops $1B as more generics challenge Adderall

Teva gets FDA approval for its own version of ADHD drug By Eric Palmer Changes are apace at Shire ($SHPG), the Irish specialty drugmaker that is something of a darling of the industry. ...

Seroquel XR patent upheld, protecting AZ blockbuster

With basic version falling to generics, AZ has been fighting for XR By Eric Palmer AstraZeneca’s ($AZN) new CEO Pascal Soriot had to start the year giving shareholders tough ...
Page 4 of 22« First...23456...1020...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS